HRP20040974A2 - Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one - Google Patents
Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-oneInfo
- Publication number
- HRP20040974A2 HRP20040974A2 HR20040974A HRP20040974A HRP20040974A2 HR P20040974 A2 HRP20040974 A2 HR P20040974A2 HR 20040974 A HR20040974 A HR 20040974A HR P20040974 A HRP20040974 A HR P20040974A HR P20040974 A2 HRP20040974 A2 HR P20040974A2
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- formula
- image
- fluorophenyl
- trifluoromethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 29
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 title description 5
- 150000001875 compounds Chemical class 0.000 claims description 36
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 24
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 14
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 10
- 150000007529 inorganic bases Chemical class 0.000 claims description 9
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 8
- 238000007363 ring formation reaction Methods 0.000 claims description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 7
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 7
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 6
- 235000002639 sodium chloride Nutrition 0.000 claims description 6
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 5
- 239000008346 aqueous phase Substances 0.000 claims description 5
- 239000003880 polar aprotic solvent Substances 0.000 claims description 5
- 235000011181 potassium carbonates Nutrition 0.000 claims description 5
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 239000001103 potassium chloride Substances 0.000 claims description 4
- 235000011164 potassium chloride Nutrition 0.000 claims description 4
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 4
- 235000017550 sodium carbonate Nutrition 0.000 claims description 4
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 claims description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 claims description 3
- GNOIPBMMFNIUFM-UHFFFAOYSA-N hexamethylphosphoric triamide Chemical compound CN(C)P(=O)(N(C)C)N(C)C GNOIPBMMFNIUFM-UHFFFAOYSA-N 0.000 claims description 3
- 238000005406 washing Methods 0.000 claims description 3
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- 238000006243 chemical reaction Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 235000015320 potassium carbonate Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- 235000011118 potassium hydroxide Nutrition 0.000 claims description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 2
- 239000011780 sodium chloride Substances 0.000 claims description 2
- 235000011121 sodium hydroxide Nutrition 0.000 claims description 2
- 239000012266 salt solution Substances 0.000 claims 3
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 claims 2
- 239000001569 carbon dioxide Substances 0.000 claims 1
- 229910002092 carbon dioxide Inorganic materials 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- 239000000203 mixture Substances 0.000 description 6
- ZLTYUAYWBAWZNO-UHFFFAOYSA-N 2-[1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-2h-1,4-oxazine Chemical compound C=1C(C(F)(F)F)=CC(C(F)(F)F)=CC=1C(C)OC1OC=CN=C1C1=CC=C(F)C=C1 ZLTYUAYWBAWZNO-UHFFFAOYSA-N 0.000 description 5
- OKKJLVBELUTLKV-MZCSYVLQSA-N Deuterated methanol Chemical compound [2H]OC([2H])([2H])[2H] OKKJLVBELUTLKV-MZCSYVLQSA-N 0.000 description 4
- 102100024304 Protachykinin-1 Human genes 0.000 description 4
- 150000003839 salts Chemical class 0.000 description 4
- 239000007858 starting material Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- QDZOEBFLNHCSSF-PFFBOGFISA-N (2S)-2-[[(2R)-2-[[(2S)-1-[(2S)-6-amino-2-[[(2S)-1-[(2R)-2-amino-5-carbamimidamidopentanoyl]pyrrolidine-2-carbonyl]amino]hexanoyl]pyrrolidine-2-carbonyl]amino]-3-(1H-indol-3-yl)propanoyl]amino]-N-[(2R)-1-[[(2S)-1-[[(2R)-1-[[(2S)-1-[[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]pentanediamide Chemical compound C([C@@H](C(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](N)CCCNC(N)=N)C1=CC=CC=C1 QDZOEBFLNHCSSF-PFFBOGFISA-N 0.000 description 2
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 101000831616 Homo sapiens Protachykinin-1 Proteins 0.000 description 2
- 101800003906 Substance P Proteins 0.000 description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- ADNPLDHMAVUMIW-CUZNLEPHSA-N substance P Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(N)=O)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CCCN=C(N)N)C1=CC=CC=C1 ADNPLDHMAVUMIW-CUZNLEPHSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- MHABMANUFPZXEB-UHFFFAOYSA-N O-demethyl-aloesaponarin I Natural products O=C1C2=CC=CC(O)=C2C(=O)C2=C1C=C(O)C(C(O)=O)=C2C MHABMANUFPZXEB-UHFFFAOYSA-N 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001411 amidrazones Chemical class 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- -1 e.g. Substances 0.000 description 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- 238000004366 reverse phase liquid chromatography Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
- C07D265/28—1,4-Oxazines; Hydrogenated 1,4-oxazines
- C07D265/30—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings
- C07D265/32—1,4-Oxazines; Hydrogenated 1,4-oxazines not condensed with other rings with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US37373402P | 2002-04-18 | 2002-04-18 | |
| PCT/US2003/011956 WO2003089429A1 (en) | 2002-04-18 | 2003-04-17 | Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20040974A2 true HRP20040974A2 (en) | 2005-06-30 |
Family
ID=29251070
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20040974A HRP20040974A2 (en) | 2002-04-18 | 2004-10-15 | Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US7847095B2 (es) |
| EP (1) | EP1499611B1 (es) |
| JP (1) | JP4271586B2 (es) |
| KR (1) | KR100982901B1 (es) |
| CN (1) | CN1293077C (es) |
| AR (1) | AR039625A1 (es) |
| AU (1) | AU2003228578B2 (es) |
| BR (1) | BR0309277A (es) |
| CA (1) | CA2482466C (es) |
| EG (1) | EG24127A (es) |
| HR (1) | HRP20040974A2 (es) |
| IL (1) | IL164586A (es) |
| MX (1) | MXPA04010182A (es) |
| NO (1) | NO330362B1 (es) |
| NZ (1) | NZ535883A (es) |
| PL (1) | PL217076B1 (es) |
| RU (1) | RU2326879C2 (es) |
| TW (1) | TWI341313B (es) |
| UA (1) | UA84399C2 (es) |
| WO (1) | WO2003089429A1 (es) |
| ZA (1) | ZA200408193B (es) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE0400850D0 (sv) * | 2004-03-30 | 2004-03-31 | Astrazeneca Ab | Novel Compounds |
| US8080656B2 (en) | 2005-10-05 | 2011-12-20 | Ranbaxy Laboratories Limited | Process for the preparation of aprepitant |
| EP1942734A4 (en) * | 2005-10-06 | 2010-04-07 | Reddys Lab Ltd Dr | PREPARATION OF THE APREPITANT |
| US9227958B2 (en) | 2006-02-03 | 2016-01-05 | Glenmark Pharmaceuticals Limited | Amorphous and crystalline forms of aprepitant and processes for the preparation thereof |
| EP2057151A4 (en) * | 2006-08-28 | 2010-07-21 | Hetero Drugs Ltd | PROCESS FOR PURIFYING APREPITANT |
| US8940890B2 (en) | 2010-05-24 | 2015-01-27 | Chengdu Di'ao Pharmaceutical Group Co., Ltd. | Preparation method of 5-[[2(R)-[1(R)-[3,5-bis(trifluoromethyl) phenyl]ethoxy]-3(S)-4-fluorophenyl-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazole-3-one |
| HUP1000325A2 (en) * | 2010-06-18 | 2012-01-30 | Druggability Technologies Ip Holdco Jersey Ltd | Nanostructured aprepitant compositions and process for their preparation |
| WO2012146692A1 (en) | 2011-04-29 | 2012-11-01 | Sandoz Ag | Novel intermediates for the preparation of highly pure aprepitant or fosaprepitant |
| CN103030668B (zh) * | 2011-10-09 | 2016-06-15 | 江苏豪森药业集团有限公司 | 一种制备福沙匹坦二甲葡胺的方法 |
| EP2817305B1 (en) * | 2012-02-23 | 2016-09-28 | Piramal Enterprises Limited | An improved process for the preparation of aprepitant |
| CZ304770B6 (cs) * | 2012-03-13 | 2014-10-08 | Zentiva, K.S. | Způsob výroby 3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluormethyl)fenyl)ethoxy)-3-(4-fluorfenyl)morfolino)methyl)-1H-1,2,4-triazol-5(4H)-onu (Aprepitantu) v polymorfní formě II |
| ITMI20130273A1 (it) * | 2013-02-26 | 2014-08-27 | Olon Spa | Procedimento per la preparazione di aprepitant |
| CN103288813A (zh) * | 2013-06-04 | 2013-09-11 | 四川百利药业有限责任公司 | 一种阿瑞匹坦的制备方法 |
| CN107954998B (zh) * | 2016-10-14 | 2022-08-12 | 江苏豪森药业集团有限公司 | 福沙匹坦中间体的制备方法 |
| CN106967057A (zh) * | 2017-06-01 | 2017-07-21 | 四川制药制剂有限公司 | 一种阿瑞匹坦高效制备工艺 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5719147A (en) | 1992-06-29 | 1998-02-17 | Merck & Co., Inc. | Morpholine and thiomorpholine tachykinin receptor antagonists |
| US5637699A (en) | 1992-06-29 | 1997-06-10 | Merck & Co., Inc. | Process for preparing morpholine tachykinin receptor antagonists |
| IL111960A (en) * | 1993-12-17 | 1999-12-22 | Merck & Co Inc | Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them |
| TW385308B (en) * | 1994-03-04 | 2000-03-21 | Merck & Co Inc | Prodrugs of morpholine tachykinin receptor antagonists |
| GB9513972D0 (en) * | 1995-07-08 | 1995-09-06 | Merck Sharp & Dohme | Pharmaceutical compositions |
| ZA985765B (en) | 1997-07-02 | 1999-08-04 | Merck & Co Inc | Polymorphic form of a tachykinin receptor antagonist. |
| GB9813025D0 (en) | 1998-06-16 | 1998-08-12 | Merck Sharp & Dohme | Chemical synthesis |
-
2003
- 2003-04-09 AR ARP030101248A patent/AR039625A1/es not_active Application Discontinuation
- 2003-04-10 TW TW092108229A patent/TWI341313B/zh not_active IP Right Cessation
- 2003-04-17 EP EP03726338.1A patent/EP1499611B1/en not_active Expired - Lifetime
- 2003-04-17 CN CNB038084465A patent/CN1293077C/zh not_active Expired - Fee Related
- 2003-04-17 JP JP2003586150A patent/JP4271586B2/ja not_active Expired - Fee Related
- 2003-04-17 RU RU2004133678/04A patent/RU2326879C2/ru not_active IP Right Cessation
- 2003-04-17 BR BR0309277-1A patent/BR0309277A/pt not_active IP Right Cessation
- 2003-04-17 NZ NZ535883A patent/NZ535883A/en not_active IP Right Cessation
- 2003-04-17 MX MXPA04010182A patent/MXPA04010182A/es active IP Right Grant
- 2003-04-17 KR KR1020047016622A patent/KR100982901B1/ko not_active IP Right Cessation
- 2003-04-17 UA UA20041109407A patent/UA84399C2/ru unknown
- 2003-04-17 PL PL373348A patent/PL217076B1/pl unknown
- 2003-04-17 WO PCT/US2003/011956 patent/WO2003089429A1/en active Application Filing
- 2003-04-17 US US10/511,691 patent/US7847095B2/en not_active Expired - Lifetime
- 2003-04-17 CA CA2482466A patent/CA2482466C/en not_active Expired - Fee Related
- 2003-04-17 AU AU2003228578A patent/AU2003228578B2/en not_active Ceased
- 2003-04-19 EG EG2003040353A patent/EG24127A/xx active
-
2004
- 2004-10-11 ZA ZA200408193A patent/ZA200408193B/en unknown
- 2004-10-14 IL IL164586A patent/IL164586A/en not_active IP Right Cessation
- 2004-10-15 HR HR20040974A patent/HRP20040974A2/hr not_active Application Discontinuation
- 2004-11-17 NO NO20045001A patent/NO330362B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| JP4271586B2 (ja) | 2009-06-03 |
| EP1499611A4 (en) | 2006-05-03 |
| PL373348A1 (en) | 2005-08-22 |
| NZ535883A (en) | 2007-12-21 |
| EP1499611A1 (en) | 2005-01-26 |
| AR039625A1 (es) | 2005-03-02 |
| NO20045001L (no) | 2004-11-17 |
| WO2003089429A1 (en) | 2003-10-30 |
| KR20050007299A (ko) | 2005-01-17 |
| MXPA04010182A (es) | 2005-02-03 |
| US20050215786A1 (en) | 2005-09-29 |
| EG24127A (en) | 2008-07-08 |
| KR100982901B1 (ko) | 2010-09-20 |
| US7847095B2 (en) | 2010-12-07 |
| CA2482466C (en) | 2012-11-20 |
| IL164586A0 (en) | 2005-12-18 |
| BR0309277A (pt) | 2005-02-22 |
| JP2005529881A (ja) | 2005-10-06 |
| RU2004133678A (ru) | 2005-05-27 |
| TWI341313B (en) | 2011-05-01 |
| NO330362B1 (no) | 2011-04-04 |
| CN1293077C (zh) | 2007-01-03 |
| PL217076B1 (pl) | 2014-06-30 |
| EP1499611B1 (en) | 2015-02-11 |
| AU2003228578A1 (en) | 2003-11-03 |
| RU2326879C2 (ru) | 2008-06-20 |
| TW200400189A (en) | 2004-01-01 |
| UA84399C2 (en) | 2008-10-27 |
| IL164586A (en) | 2010-11-30 |
| ZA200408193B (en) | 2006-06-28 |
| CA2482466A1 (en) | 2003-10-30 |
| CN1646525A (zh) | 2005-07-27 |
| AU2003228578B2 (en) | 2009-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20040974A2 (en) | Process for 5-[[2(r)-[1(r)-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3(s)-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3h-1,2,4-triazol-3-one | |
| EP2771004B1 (en) | Inhibitors of the renal outer medullary potassium channel | |
| KR101373902B1 (ko) | 신장 바깥 수질 포타슘 채널의 억제제 | |
| TWI460166B (zh) | 製備２-亞胺基-四氫噻唑-４-酮衍生物之新穎方法 | |
| EP2599781A1 (en) | Processes for the preparation of sitagliptin and pharmaceutically acceptable salts thereof | |
| JP2019194191A (ja) | ビロキサジン塩を製造する方法及びその新規な多形 | |
| CA2961984A1 (en) | Novel chiral synthesis of n-acyl-(3-substituted)-(8-substituted)-5,6-dihydro-[1,2,4]triazolo[4,3-a]pyrazines | |
| TWI225055B (en) | Process for the preparation of 5-substituted isobenzofurans | |
| US20030187274A1 (en) | Process for the preparation of 1,2,4- triazolin-5-one derivatives | |
| JP2022535112A (ja) | ４－フェニル－５－アルコキシカルボニル－２－チアゾール－２－イル－１，４－ジヒドロピリミジン－６－イル］メチル］－３－オキソ－５，６，８，８ａ－テトラヒドロ－１Ｈ－イミダゾ［１，５－ａ］ピラジン－２－イル］－カルボン酸を調製するための代替方法 | |
| US20020016458A1 (en) | Intramolecular glycosidation process for the synthesis of (2R, 2-alpha-R, 3A)-2-[1-(3,5- BIS (trifluoromethyl)phenyl)ethoxy]-3-(4-fluorophenyl)-1,4-oxazine | |
| KR100986734B1 (ko) | 모사프리드 제조용 중간체의 제조방법 | |
| GB2281297A (en) | Quinazoline compounds | |
| JP2002356480A (ja) | トランス−（５ｒ）−２，４，５−トリ置換２−オキサゾリンの製造方法 | |
| JPH04270272A (ja) | アミノアルキルモルホリン誘導体の製造法 | |
| JP3573364B2 (ja) | 新規なｎ−（２−シンナミルアミノエチル）ナフタレンスルフォンアミド誘導体 | |
| EA046640B1 (ru) | Способ и промежуточное соединение для получения оксетан-2-илметанамина | |
| JP2005350390A (ja) | ３−アミノフラボン化合物の製造方法 | |
| JPH07247275A (ja) | オキサゾリジノン誘導体の単一のジアステレオマーの製造方法及びウレタン化合物の単一のジアステレオマーのフマル酸塩 | |
| JPH0748367A (ja) | ビシクロアミン誘導体 | |
| JP2000191650A (ja) | オキサゾリジノン誘導体の製法 | |
| NO171213B (no) | Pyrazolo(1,5-a)pyrimidiner, saerlig egnet for anvendelse som mellomprodukt |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A1OB | Publication of a patent application | ||
| ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
| PNAN | Change of the applicant name, address/residence |
Owner name: MERCK SHARP & DOHME CORP., US |
|
| PNAN | Change of the applicant name, address/residence |
Owner name: MERCK SHARP & DOHME CORP., US Owner name: SCHERING CORPORATION, US |
|
| ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20140410 Year of fee payment: 12 |
|
| OBST | Application withdrawn |